Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening

Canadian Journal of Gastroenterology

Volumn 22, Issue 11, 2008, Pages 923-930

  McLaren, Gordon D ^a,b   McLaren, Christine E ^b   Adams, Paul C ^c   Barton, James C ^d   Reboussin, David M ^e   Gordeuk, Victor R ^f   Acton, Ronald T ^g   Harris, Emily L ^h,i   Speechley, Mark R ^j   Sholinsky, Phyliss ^k   Dawkins, Fitzroy W ^f   Snively, Beverly M ^e   Vogt, Thomas M ^l   Eckfeldt, John H ^m  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d SOUTHERN IRON DISORDERS CENTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g University of Alabama at Birmingham   (United States)

^h CENTER FOR HEALTH RESEARCH   (United States)

ⁱ NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF WESTERN ONTARIO   (Canada)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^l KAISER PERMANENTE   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

Complications; Cross sectioned study; Hemochromatosis; HFE; Iron overload; Prevalence

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HFE PROTEIN; DNA; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; HEART DISEASE; HEMOCHROMATOSIS; HEPATOMEGALY; HOMOZYGOSITY; HUMAN; HYPERPIGMENTATION; JOINT STIFFNESS; JOINT SWELLING; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METACARPOPHALANGEAL JOINT; PHLEBOTOMY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; WILD TYPE; AGE DISTRIBUTION; BLOOD; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; RISK FACTOR; SEX RATIO; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALLELES; CANADA; CROSS-SECTIONAL STUDIES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; UNITED STATES;

EID: 59149090150     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/907356     Document Type: Article

References (52)

1. Powell LW, Jazwinska E, Halliday JW. Primary iron overload. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. Philadelphia: WB Saunders, 1994:227-270.
2. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-97.
3. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
4. Gordeuk VR, McLaren GD, Samowitz W. Etiologies, consequences and treatment of iron overload. Crit Rev Clin Lab Sci 1994;31:89-133.
5. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
6. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
7. Edwards CQ, Ajioka RS, Kushner JP. Hemochromatosis: A genetic definition. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, United Kingdom: Cambridge University Ptess;2000:8-11.
8. Rochette J, Pointon JJ, Fisher CA, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999;64:1056-62. [Erratum in Am J Hum Genet 1999;64:1491.].
9. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-98.
10. Acton RT, Barton JC, Snively BM, et al. Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis 2006;16:815-21.
11. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 200l;154:193-206.
12. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
13. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
14. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522-36.
15. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-15.
16. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G → A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
17. Asberg A, Hveem K, Kruger O, Bjerve KS. Persons with screening-detected haemochromatosis: As healthy as the general population? Scand J Gastroenterol 2002;37:719-24.
18. McCune CA, Ravine D, Carter K, et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 2006;55:554-62.
19. US Preventive Services Task Force. Screening for hemochromatosis: Recommendation statement. Ann Intern Med 2006;145:204-8.
20. McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003;325:53-62.
21. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
22. Jeffrey GP, Chakrabarti S, Hegele RA, Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet 1999;22:325-6.
23. Adams PC, Reboussin DM, Leiendecker-Foster C, et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) Study. Clin Chem 2005;51:1048-52.
24. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
25. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-62.
26. Phatak PD, Sham RL, Raubertas RF, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998;129:954-61.
27. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
28. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005;366:314-6.
29. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006;145:209-23.
30. Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 2003;101:3351-3.
31. Watkins S, Thorburn D, Joshi N, et al. The biochemical and clinical penetrance of individuals diagnosed with genetic haemochromatosis by predictive genetic testing. Eur J Gastroenterol Hepatol 2008;20:379-83.
32. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: Meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007;46:1071-80.
33. Worwood M. Determination of iron status In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. Philadelphia: WB Saunders, 1994:449-76.
34. Swinkels DW, Aalbers N, Elving LD, Bleijenberg C, Swanink CM, van der Meer JW. Primary haemochromatosis: A missed cause of chronic fatigue syndrome? Neth J Med 2002;60:429-33.
35. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
36. Acton RT, Barton JC, Bell DS, Go RC, Roseman JM. HFE mutations in African-American women with non-insul-independent diabetes mellitus. Ethn Dis 2001;11:578-84.
37. Acton RT, Barton JC, Passmore LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006;29:2084-9.
38. Salonen JT, Tuomainen TP, Kontula K. Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: Prospective cohort study. BMJ 2000;320:1706-7.
39. Adams PC, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology 1998;114:319-23.
40. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294-301.
41. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: A changing scene. Am J Med 1991;90:445-9.
42. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
43. Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatobogy 2006;44:472-7.
44. Asberg A, Hveem K, Halvorsen TB, Smethurst HB. Prevalence of liver fibrosis and cirrhosis in screening-detected C282Y homozygous subjects. Scand J Gastroenterol 2007;42:782-3.
45. Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006;4:918-23.
46. Adams PC. Screening for haemochromatosis - producing or preventing illness? Lancet 2005;366:269-71.
47. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Intern Med 2003;138:627-33. [Erratum in Ann Intern Med 2003;139:235].
48. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999;130:953-62.
49. Edwards CQ, Griffen LM, Kushner JP. The morbidity of hemochromatosis among clinically unselected homozygotes: Preliminary report. Adv Exp Med Biol 1994;356:303-8.
50. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK. Screening for hereditary hemochromatosis: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2005;143:517-21.
51. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: Iron overload progression rate. Blood 2004;103:2914-9.
52. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: A 17-year study. Mayo Clin Proc 2004;79:309-13.